PBN.F Alterity Therapeutics Limited

Healthcare Biotechnology Frankfurt Exchange
0.1400 EUR
Close of Nov 12, 2026
0.1000 0.4140
Market cap
EUR 32.1M
P/E
-
P/B
1.56x
ROE
-54.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is PBN.F undervalued?

Graham number

The Graham number of Alterity Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alterity Therapeutics Limited fundamental analysis

No fundamental analysis for Alterity Therapeutics Limited yet.

Alterity Therapeutics Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alterity Therapeutics Limited

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 tha…

Full company profile